Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > BIND Biosciences, Inc. Awarded NIH Phase I SBIR Contract to Develop Therapeutic Targeted Nanoparticles for Prostate Cancer Therapy

Abstract:
BIND Biosciences, Inc. (BIND), a privately held biopharmaceutical company focused on developing therapeutic targeted nanoparticles, announced today that it has been awarded a six month $150,000 Phase I SBIR contract from the National Cancer Institute (NCI) to develop a targeted therapy for hormone refractory prostate cancer (HRPC). Prostate cancer accounts for an estimated 27,000 annual deaths in the U.S. and is an area of enormous unmet medical need.

BIND Biosciences, Inc. Awarded NIH Phase I SBIR Contract to Develop Therapeutic Targeted Nanoparticles for Prostate Cancer Therapy

Cambridge, MA | Posted on October 8th, 2007

"The NCI SBIR funding is one important validation of BIND's therapeutic targeted nanoparticle platform and will accelerate our prostate cancer program," according to Dr. Jeff Hrkach, Vice President of Pharmaceutical Sciences at BIND and the Principal Investigator on this Phase I SBIR program. "By utilizing BIND's targeted polymeric nanoparticle technology, we will be able to develop revolutionary therapies to address prostate cancer."

"BIND was founded, in-part, based on technologies that were developed through a $20M NCI funded Center for Cancer Nanotechnology Excellence. We view this SBIR contract as a continued collaboration with the NCI as we move toward commercializing breakthrough therapies for important human diseases, including cancer," said Glenn Batchelder, President and Chief Executive Officer of BIND. "We are very fortunate to have Dr. Hrkach leading this program with his extensive expertise in polymeric particle drug delivery and his broad drug development experience accumulated during his tenures at Advance Inhalation Research, Alkermes and Momenta."

The NCI SBIR program is a peer-reviewed competitive funding process that provides research support to companies discovering and developing innovative biomedical products for the treatment and diagnosis of cancer. Companies that successfully meet the goals of this Phase I program are eligible to apply for an additional $1,000,000 in Phase II support to continue their development efforts. This work builds on nanoparticle technologies that were originally developed by BIND's scientific founders, Dr. Robert Langer (MIT) and Dr. Omid Farokhzad (Brigham and Women's Hospital - Harvard Medical School) and BIND has licensed the large patent estate covering these technologies on a worldwide exclusive basis.

####

About BIND Biosciences, Inc.
BIND Biosciences is a privately held biopharmaceutical company focused on developing therapeutic targeted nanoparticles. The companyís product-platform leverages the convergence of polymeric biomaterials, nanoparticle engineering and combinatorial synthesis to uniquely enable BIND to design and optimize targeted nanoparticle therapeutics for specific indications. BINDís technology concentrates drug at the intended site of action while minimizing systemic exposure, thereby improving efficacy and reducing off-target effects.

The companyís platform is broadly applicable across therapeutic areas with the initial product development efforts focused in cancer and cardiovascular disease. The company anticipates initiating clinical trials for their first product in 2009. Founded in 2006 and backed by leading venture capital firms, Flagship Ventures and Polaris Venture Partners, BIND is based in Cambridge, Massachusetts.

For more information, please click here

Contacts:
BIND Biosciences, Inc.
Glenn Batchelder, President and CEO, 617-491-3400

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Govt.-Legislation/Regulation/Funding/Policy

Electro-optical switch transmits data at record-low temperatures: Operating at temperatures near absolute zero, switch could enable significantly faster data processing with lower power consumption March 20th, 2017

AIM Photonics Welcomes Coventor as Newest Member: US-Backed Initiative Taps Process Modeling Specialist to Enable Manufacturing of High-Yield, High-Performance Integrated Photonic Designs March 16th, 2017

Researchers develop groundbreaking process for creating ultra-selective separation membranes: Discovery could greatly improve energy-efficiency of separation and purification processes in the chemical and petrochemical industries March 15th, 2017

Nanogate Expands Sustainability Management: Nanogate publishes a statement of compliance with the German Sustainability Code for the first time March 15th, 2017

Nanomedicine

Nanoparticle paves the way for new triple negative breast cancer drug March 20th, 2017

Block copolymer micellization as a protection strategy for DNA origami March 17th, 2017

Nanocages for gold particles: what is happening inside? March 16th, 2017

Biophysicists propose new approach for membrane protein crystallization March 8th, 2017

Announcements

Caught on camera -- chemical reactions 'filmed' at the single-molecule level March 22nd, 2017

Rare-earths become water-repellent only as they age March 22nd, 2017

Pulverizing e-waste is green, clean -- and cold: Rice, Indian Institute researchers use cryo-mill to turn circuit boards into separated powders March 21st, 2017

CRMGroup in Belgium uses a Deben three point bending stage in the development of new steel & coated steel products for automotive and other industrial applications March 21st, 2017

Grants/Sponsored Research/Awards/Scholarships/Gifts/Contests/Honors/Records

Rice lab expands palette for color-changing glass: Nanophotonics team creates low-voltage, multicolor, electrochromic glass March 8th, 2017

Sandia use confined nanoparticles to improve hydrogen storage materials performance: Big changes from a small package for hydrogen storage February 25th, 2017

Oxford Instruments announces Dr Brad Ramshaw of Cornell University, as winner of the 2017 Lee Osheroff Richardson Science Prize February 20th, 2017

Nominations Invited for $250,000 Kabiller Prize in Nanoscience: Major international prize recognizes a visionary nanotechnology researcher February 20th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project